Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

Allogeneic, T SCM -rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026 Poseida Cell Therapy R&D Day to take place on Thursday, November 14 at 7 am PT / 10 am ET